OSTILL / SHUTTERSTOCK.COM

3 March 2015AmericasGunars Gaikis

Generics in Canada: The race for market exclusivity

The Supreme Court of Canada has tentatively set April 20, 2015 as the date for the hearing of Sanofi’s appeal against a court’s decision that the company is liable for generic drug maker Apotex’s lost sales of ramipril based on section 8 of the Patented Medicines (Notice of Compliance) Regulations (NOC Regulations).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

More on this story

More on this story

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’

BMS unit loses cell therapy patent at European Patent Office

Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market

Bankruptcy judge approves $305m sale of genetics testing company

Sanofi successfully challenges rare disease patent in Europe

WATCH: Policy direction—where are we now?

Broad Institute wins appeal to restore CRISPR patent in Europe

BMS faces fresh lawsuit over alleged cancer drug monopoly